Turn Therapeutics Secures Up to $25M Debt Facility, Extends Runway for Clinical Programs
Summary
Turn Therapeutics Inc. secured a new loan and security agreement for up to $25 million, with an initial $7 million funded, to extend its operational runway and advance clinical trials for atopic dermatitis and onychomycosis.
Key Events
-
Secured $25M Loan Facility
Turn Therapeutics entered into a Loan and Security Agreement for up to $25 million, with an initial $7 million funded immediately.
-
Extends Operational Runway
The financing is expected to extend the company's runway through its Phase 2 atopic dermatitis readout and potentially through the end of 2027 if all tranches are funded.
-
Dilutive Equity Components
The agreement includes an immediate $1.2 million equity grant to the lender and a conversion option for up to $3 million of principal into common stock at 80% of the trading price.
-
Asset-Backed Debt with High Interest
The loan is secured by all company assets, including intellectual property, and carries a minimum annual interest rate of 12.25%.
Analysis
Turn Therapeutics Inc. has secured a significant growth capital loan facility of up to $25 million from Avenue Venture Opportunities Fund II, L.P. This financing is critical for the clinical-stage company, providing an immediate $7 million in funding to extend its operational runway and support the advancement of its atopic dermatitis and onychomycosis clinical programs. While the financing ensures continued operations, it comes with substantial costs, including a high minimum annual interest rate of 12.25% and a lien on all company assets, including intellectual property. Additionally, the agreement includes dilutive components: an immediate $1.2 million equity grant to the lender and a conversion option for up to $3 million of outstanding principal into common stock at a discount (80% of the trading price). The availability of subsequent tranches (up to $18 million) is contingent upon achieving specified clinical and financing milestones, introducing future uncertainty but also potential for further capital.
At the time of this filing, TTRX was trading at $3.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $100.7M. The 52-week trading range was $2.57 to $26.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.